When cancer is deprived of essential nutrients Acetate is the fuel

Glucose is one of the principal fuels when it comes to cancer cells. More recently it has become clear that other fuel sources, including glutamine, lipids, and protein also play an important role in cancer. However, I was not aware about the relevance of acetate as a fuel for cancer cells.

Indeed, while acetate can be produced locally within the cell it has been recently shown that a variety of cancers are also capable of capturing (from outside the cell) and metabolizing acetate, and that this represents a metabolic adaptation that some tumors use to facilitate growth.

To me, the discovery of the acetate relevance in cancer is huge. Here are at least two reasons for that:

  1. “acetate as a fuel” may explain how cancer cells may become resistant to e.g. angiogenesis inhibitors. On this line, one great scientist was mentioning to me that she saw tumors growing without any blood supply. Well, acetate may explain that since normal cells or tissues might actually represent net producers of acetate, and off course they are the neighbors of tumor cells, potentially supplying the cancer cells with the much needed acetate
  2. as discussed below, a natural supplement HCA inhibitor of the enzyme that converts citrate into acetyl-CoA has been shown to reduce tumors … but that usually happens for a while only until tumors start grow again. Again, “acetate as a fuel” may explain the acquired resistance to HCA since direct conversion of acetate to acetyl-CoA can again address the cellular need for acetyl-CoA

This means to me that that inhibiting the acetate usage may represent the solution to cancer in combination with angiogenessis inhibitors (such as Thalidomide or others) and or ACLY inhibitors (such as HCA or others).

This is why acetate has an important role:

puzzelWhen acetate is “connected” to coenzyme A inside the cell, they form acetyl-CoA. Acetyl-CoA is among the most important cellular components. It is usually generated within the cells by the oxidation (within the mitochondria, i.e. within the engine of the cell) of glucose, glutamine, or fatty acids. Once the cell has produced acetyl-CoA, this can be converted to essential elements for the cell survival and division such as to biosynthesize nucleotides, amino acids, and essential components of the cell membrane in mammals (i.e. fatty acids and cholesterol). It also contributes to enzyme and gene regulation. As we can imagine, all this components are strongly needed in fast dividing cells and are very limited in cancer cells since mitochondria are known to not work well in cancer (due to e.g. oxygen deprivation or low intracellular pH) and produce not enough acetyl-CoA.

For example, acetyl-CoA is the precursor for both fatty acid and cholesterol biosynthesis, and fatty acid synthase (FASN) is upregulated and essential in some cancers. (Ref)

At the cost of a single ATP, one acetate molecule can be retrieved to produce acetyl-CoA for use in the synthesis of fatty acids or sterols, for the acetylation of histones, or for further oxidation via the TCA cycle to generate an additional ∼12 units of ATP (Figure 6). Acetate can also be used for the synthesis of the amino acid glutamate (Mashimo et al., 2014). Unlike yeast, mammals lack a glyoxylate cycle and therefore cannot utilize acetate for the synthesis of glucose. Nonetheless, the ability to recoup acetate for any of these other purposes stands to promote tumor cell growth or survivability in the face of nutritionally challenging or hypoxic microenvironments. In contrast, acetate might be irrelevant for nutritionally replete cells or tissues. Given ample supplies of glucose, coupled with the ability to convert glucose into acetyl-CoA via citrate spilling out of mitochondria, normal cells or tissues might actually represent net producers of acetate, rather than net consumers. (Ref.)

So Acetyl-CoA is the universal metabolic source for all major cellular functions. (Ref)

Although a little complex, the image below shows various points where acetyl-CoA is produced and how that is used inside the cell.

acetylCoA

Reference for the fig. above: Acetate as a Metabolic and Epigenetic Modifier of Cancer Therapy

As it can be seen in the fig above Acetyl-CoA can be produced inside the cell via different processes enabled by enzymes such as ACSS1, ACSS2, ACYL. If is to believe that the fig above indeed represents the reality of the intra cellular processes, in cancer cells where mitochondria would be dysfunctional (due to e.g. limitted oxygen) the most important processes for the production of Acetyl-CoA would become those taking place outside mitochondria, e.g. in the cytoplasm or nucleus. (Ref.) As represented in the fig. above the production of Acetyl-CoA independent on the mitochondria relies on acetate as a source and ACSS2 enzyme required to convert acetate into Acetyl-CoA.

The above suggests that
– reducing the available intracellular acetate (imported from extra cellular sources) and/or
– inhibiting the ACSS2 enzyme (Ref.)
should have strong negative impact on the development of cancer cells or at least on those that have dysfunctional mitochondria or that are deprived of the essential nutrients such as glucose, glutamine and fatty acids.

Extra cellular sources of acetate:

Acetate is produced in the liver from acetyl-CoA and released into the circulation. Therefore, hepatic mitochondria are a major systemic source of acetate. Acetate and ethanol are also produced by microbial fermentation in the intestine. In this case, ethanol is then converted to acetate in two enzymatic steps catalyzed by alcoholdehydrogenase and aldehyde dehydrogenase 2. The acetate is either utilized locally within the intestine or released to the general circulation. (Ref.)

Acetate is a two-carbon monocarboxylic acid (i.e. a fatty acid). When it reaches the tissues, acetate is taken up and transported through cell surface monocarboxylate transporters (MCTs) and converted back into acetyl-CoA by acetyl-CoA synthetase enzymes (ACSS1, ACSS2, ACSS3). As discussed above, in cancer cells this conversion is facilitate by the acetyl-CoA synthetase enzyme 2 (ACSS2). (Ref)
.
Acetyl-CoA synthetase enzyme 2 (ACSS2)

Indeed, it has been shown that metabolic stress induces major changes in the lipid metabolism landscape of cancer cells, creating a dependence on de novo lipogenesis for survival in hypoxia/low serum (Ref.). In this context, nucleocytosolic acetyl-CoA synthetase enzyme ACSS2 becomes up regulated and is a critical gene for cancer cell survival under hypoxic or low-serum conditions (Ref.). This is how for example GBM or brain metastases can completely oxidize acetate in the tumors (Ref.).
Interestingly, the source of the intracellular acetate resulting from hypoxia and its mobilization is not known (Ref.).

So what this knowledge means for us and how we can apply it in cancer treatment?

Acetyl-CoA is essential in cancer cells and lowering the availability of that will have negative impact on tumor development. This may be the approaches to achieve that:

  • In case mitochondria is functional and produces elements required for acetyl-CoA, I would consider inhibiting ATP citrate lyase enzyme (ACLY). This can be inhibited by hydroxycitric acid (HCA) (Ref) which can be found in the online shops as a Garcinia Cambogia extract supplement.
    Indeed HCA in combination with Alpha Lipoic Acid (ALA) has been previously proposed and patented by Dr. Laurent Schwartz et al. (Ref) as a anti cancer combination (METABLOC). Furthermore, is has been demonstrated in humans that this combination of ALA and HCA is efficient against cancer cell proliferation (Ref). Unfortunately, while these were clearly great results, the effectiveness of the combination may be reduced in time by the tumors. It is now interesting to realize that this reduction in effectiveness was probably due to a switch to e.g. the production of acetyl-CoA based on acetate and ACSS2.
    .
  • In case mitochondria is not functional, that we need to focus on acetate and ACSS2. On this line,
    .

    • one option would be to lower the acetate production in the liver and  lower the production of acetate in the intestine by avoiding food fermentation. This reminds me of a naturophat who was suggesting not to eat fruits and vegetables at the same time and always start the meal by first eating the fruits, wait a bit and then eat the main meal in order to avoid fermentation.
      .
    • the other options would be to reduce the take up of acetate in the cancer cells by inhibiting MCTs, specifically MCT1. The inhibitors of MCT1 were extensively discussed on this website in the context of 3BP since MCT1 is also the main transporter transporting 3BP within the cancer cells. MCT1 inhibitors discussed in this context were e.g. Quercetin, Apigenin, Ibuprofen, Statins, etc.
      Indeed MCT1 is one of the targets for anti cancer drug manufacturers since MCT1 is not only used by cancer cells to take up acetate but also lactate. (Ref) However, I am not sure if they realized that by inhibiting MCT1 were limiting not only lactate but also acetate access in to the cancer cell which is off course very good.
      .
    • finally another options is to inhibit the expression of ACSS2 enzyme – I am still searching for a good and accessible inhibitor
      Quinoxaline seems to be one of the inhibitors found in Ref. It seems that this substance and its derivatives has many pharmacological activities like antibacterial, antifungal, antituberculer, anti-inflammatory, antihyperglycemic, antitumor etc. (Ref.)
      .
      Update: 10-April-2017: when ACLYL is inhibited by HCA, tumor cells will express ACSS2 enzyme to convert acetate into the actyl-CoA (Ref.). ACSS2 level is modulated by SREBP2 (Ref.) and SREBP2 in turn can be modulated by Vitamin E derivatives (tocotrienols) (Ref.)

      • Dose: not yet sure what would be the best dose
      • Source: Online available supplements such as this one.
        Note: Thank you to Frank Liu for heads up on this point via his comment.

Note: the fact that in hypoxia regions acetate may be even more required makes me realize that MCT1 should be still ‘(over) expressed towards the core of the tumors. Previously, I though this may not be the case since I thought that MCT1 is overexpressed only in those areas where oxygen is also available so that it can make use of lactate as a source of energy. MCT1 towards the core of the tumor is good news to me since that indicates a maintained sensitivity to 3BP beyond the surface of tumors.

References:

Putting the brakes on tumor growth

Acetate as a Metabolic and Epigenetic Modifier of Cancer Therapy: Metabolic networks are significantly altered in neoplastic cells. This altered metabolic program leads to increased glycolysis and lipogenesis and decreased dependence on oxidative phosphorylation and oxygen consumption. Despite their limited mitochondrial respiration, cancer cells, nonetheless, derive sufficient energy from alternative carbon sources and metabolic pathways to maintain cell proliferation. They do so, in part, by utilizing fatty acids, amino acids, ketone bodies and acetate, in addition to glucose. The alternative pathways used in the metabolism of these carbon sources provide opportunities for therapeutic manipulation. Acetate, in particular, has garnered increased attention in the context of cancer as both an epigenetic regulator of posttranslational protein modification, and as a carbon source for cancer cell biomass accumulation. However, to date, the data have not provided a clear understanding of the precise roles that protein acetylation and acetate oxidation play in carcinogenesis, cancer progression or treatment. This review highlights some of the major issues, discrepancies and opportunities associated with the manipulation of acetate metabolism and acetylation-based signaling in cancer development and treatment.

Inhibitors of mammalian acetyl-CoA carboxylase.

Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress: A functional genomics study revealed that the activity of acetyl-CoA synthetase 2 (ACSS2) contributes to cancer cell growth under low-oxygen and lipid-depleted conditions. Comparative metabolomics and lipidomics demonstrated that acetate is used as a nutritional source by cancer cells in an ACSS2-dependent manner, and supplied a significant fraction of the carbon within the fatty acid and phospholipid pools. ACSS2 expression is upregulated under metabolically stressed conditions and ACSS2 silencing reduced the growth of tumor xenografts. ACSS2 exhibits copy-number gain in human breast tumors, and ACSS2 expression correlates with disease progression. These results signify a critical role for acetate consumption in the production of lipid biomass within the harsh tumor microenvironment.

Cytosolic acetyl-CoA synthetase affected tumor cell survival under hypoxia: the possible function in tumor acetyl-CoA/acetate metabolism. Understanding tumor-specific metabolism under hypoxia is important to find novel targets for antitumor drug design. Here we found that tumor cells expressed higher levels of cytosolic acetyl-CoA synthetase (ACSS2) under hypoxia than normoxia. Knockdown of ACSS2 by RNA interference (RNAi) in tumor cells enhanced tumor cell death under long-term hypoxia in vitro. Our data also demonstrated that the ACSS2 suppression slowed tumor growth in vivo. These findings showed that ACSS2 plays a significant role in tumor cell survival under hypoxia and that ACSS2 would be a potential target for tumor treatment. Furthermore, we found that tumor cells excreted acetate and the quantity increased under hypoxia: the pattern of acetate excretion followed the expression pattern of ACSS2. Additionally, the ACSS2 knockdown led to a corresponding reduction in the acetate excretion in tumor cells. These results mean that ACSS2 can conduct the reverse reaction from acetyl-CoA to acetate in tumor cells, which indicates that ACSS2 is a bi-directional enzyme in tumor cells and that ACSS2 might play a buffering role in tumor acetyl-CoA/acetate metabolism.

Acetate Fuels the Cancer Engine Cancer cells have distinctive nutrient demands to fuel growth and proliferation, including the disproportionate use of glucose, glutamine, and fatty acids. Comerford et al. and Mashimo et al. now demonstrate that several types of cancer are avid consumers of acetate, which facilitates macromolecular biosynthesis and histone modification.

Acetate Dependence of Tumors Acetyl-CoA represents a central node of carbon metabolism that plays a key role in bioenergetics, cell proliferation, and the regulation of gene expression. Highly glycolytic or hypoxic tumors must produce sufficient quantities of this metabolite to support cell growth and survival under nutrient-limiting conditions. Here, we show that the nucleocytosolic acetyl-CoA synthetase enzyme, ACSS2, supplies a key source of acetyl-CoA for tumors by capturing acetate as a carbon source. Despite exhibiting no gross deficits in growth or development, adult mice lacking ACSS2 exhibit a significant reduction in tumor burden in two different models of hepatocellular carcinoma. ACSS2 is expressed in a large proportion of human tumors, and its activity is responsible for the majority of cellular acetate uptake into both lipids and histones. These observations may qualify ACSS2 as a targetable metabolic vulnerability of a wide spectrum of tumors.

Acetate Is a Bioenergetic Substrate for Human Glioblastoma and Brain Metastases Glioblastomas and brain metastases are highly proliferative brain tumors with short survival times. Previously, using 13C-NMR analysis of brain tumors resected from patients during infusion of 13C-glucose, we demonstrated that there is robust oxidation of glucose in the citric acid cycle, yet glucose contributes less than 50% of the carbons to the acetyl-CoA pool. Here, we show that primary and metastatic mouse orthotopic brain tumors have the capacity to oxidize [1,2-13C]acetate and can do so while simultaneously oxidizing [1,6-13C]glucose. The tumors do not oxidize [U-13C]glutamine. In vivo oxidation of [1,2-13C]acetate was validated in brain tumor patients and was correlated with expression of acetyl-CoA synthetase enzyme 2, ACSS2. Together, the data demonstrate a strikingly common metabolic phenotype in diverse brain tumors that includes the ability to oxidize acetate in the citric acid cycle. This adaptation may be important for meeting the high biosynthetic and bioenergetic demands of malignant growth.

Characterization of acetate transport in colorectal cancer cells and potential therapeutic implications. https://www.ncbi.nlm.nih.gov/pubmed/27661124

Acetate, together with other short chain fatty acids has been implicated in colorectal cancer (CRC) prevention/therapy. Acetate was shown to induce apoptosis in CRC cells. The precise mechanism underlying acetate transport across CRC cells membrane, that may be implicated in its selectivity towards CRC cells, is not fully understood and was addressed here. We also assessed the effect of acetate in CRC glycolytic metabolism and explored its use in combination with the glycolytic inhibitor 3-bromopyruvate (3BP). We provide evidence that acetate enters CRC cells by the secondary active transporters MCT1 and/or MCT2 and SMCT1 as well as by facilitated diffusion via aquaporins. CRC cell exposure to acetate upregulates the expression of MCT1, MCT4 and CD147, while promoting MCT1 plasma membrane localization. We also observed that acetate increases CRC cell glycolytic phenotype and that acetate-induced apoptosis and anti-proliferative effect was potentiated by 3BP. Our data suggest that acetate selectivity towards CRC cells might be explained by the fact that aquaporins and MCTs are found overexpressed in CRC clinical cases. Our work highlights the importance that acetate transport regulation has in the use of drugs such as 3BP as a new therapeutic strategy for CRC.

The metabolic fate of acetate in cancer http://www.nature.com/nrc/journal/v16/n11/abs/nrc.2016.87.html

Recent high-profile reports have reignited an interest in acetate metabolism in cancer. Acetyl-CoA synthetases that catalyse the conversion of acetate to acetyl-CoA have now been implicated in the growth of hepatocellular carcinoma, glioblastoma, breast cancer and prostate cancer. In this Review, we discuss how acetate functions as a nutritional source for tumours and as a regulator of cancer cell stress, and how preventing its (re)capture by cancer cells may provide an opportunity for therapeutic intervention.

error

Related Articles


33 thoughts on “When cancer is deprived of essential nutrients Acetate is the fuel

  1. I think this means : we can kill cancer by 3-BP

    and when cancer became resistant to 3-BP (by lowering MCTs) cancer cells also will lose some of the important fuels like acetate

    so it’s better always to use MCTs against cancer (by 3-BP) until it done the job and MCTs became mostly inhibited

    but of course 3-BP should be administrated in a good way to achieve that

    or maybe that’s what I think ! , I’m not sure 🙂

  2. Dear Daniel,

    Great article.

    I have a question and would be glad if you could help me out. You wrote that the garcinia cambogia extract could be helpful in case mitochondria is functional. I was wondering how to actually know that. I always thought it was not fully functional in cancer cells, but obviously this is wrong..

    Thank you

    1. Dear Murat,

      There are various theories and observations regarding the role and state of mito in cancer. However, I believe that most of the tumors contain various types of populations with high flexibility in adapting their source of energy and building blocks. If this is the case, there is no point for us to spend time trying to understand what type of cells we are dealing with since they can also change. I am also not aware about a reliable way to investigate that given the multitude of populations characteristic to advanced cancers. Therefore, regardless of the cancer type I would always try to address both the glyco and mitho and next to that as many escape routes as possible. Such treatment strategy could than be balanced towards the typical escape routes known for specific tumor types.

      Kind regards,
      Daniel

      1. Re Mito, I always contraversial information. Many people claim cancer cells lack functional mito but is was proven to be wrong.

        Cisplatin sensitivity depends on functional mito – and many cancers are sensitive to it. Also, some cancers increase mitochondrial DNA in the blood – and yet have lower mitohcondrial respiration. Then we have the reversed warburg effect when cancer cells start to rely on mito instead of nucleus. This is clearly a complicated topic. Also, when Seyfried refers to studies showing that the transport of mito leads to cancer in mise and not the transport of nucleus it also shows that the mito must be screwed up and not simple silent.

        Probably we can conclude that the mito is either silenced (rare) or mutated but even when its functional its not being used a lot by cancer. I read a case where the Mitochondrial dna was extremely high yet the oxidative respiration was very low…

    1. Thank you Carl for the links. Very interesting research. Indeed, cancer cells have multiple escape routes. Those are their strong points but also weak spots since they depend on those. As soon as I can, I will try to address more of those points. Also, I did nor forget about your question regarding the Foundation. Just that it takes a bit more time (due to my current job). But what is important is that even if they go a little slower now, things go forward and I expect this year there will come a time when things will go fast. For now, I am considering to put a plan together and post it so that visitors can help me improve that with their suggestions / feedback.

      1. Daniel, All, what do you think about the statements from at the bottom ??? are not these findings in full contradiction with what Seyfried, Swartz etc are saying?

        IF more ATP is produced by the mitochondria in cancer cells ( more than 50% at least) then glycolitic are treatments are never enough as they dont silence the mitochondria…….

        How to to silence mito other than the following tools?

        – Metformin
        – 3 -BP
        – CA
        – glutamine inhibitor EGCG

        cheers,
        W

        https://www.ncbi.nlm.nih.gov/pubmed/14697210
        Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun. 2004;313:459–465. A report that highlights that most cancer cells generate the majority of their ATP from mitochondria

        https://www.ncbi.nlm.nih.gov/pubmed/14697210
        43. Fan J, et al. Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol. 2013;9:712. [PMC free article] [PubMed]

        1. and a third one…
          Contrary to conventional wisdom, functional mitochondria are essential for the cancer cell. Although mutations in mitochondrial genes are common in cancer cells, they do not inactivate mitochondrial energy metabolism but rather alter the mitochondrial bioenergetic and biosynthetic state. These states communicate with the nucleus through mitochondrial ‘retrograde signalling’ to modulate signal transduction pathways, transcriptional circuits and chromatin structure to meet the perceived mitochondrial and nuclear requirements of the cancer cell. Cancer cells then reprogramme adjacent stromal cells to optimize the cancer cell environment. These alterations activate out-of-context programmes that are important in development, stress response, wound healing and nutritional status.

          https://www.ncbi.nlm.nih.gov/pubmed/23001348

        2. Hi W,

          Am not sure what Seyfried says but this article by Guppy is not a very profound one. They are just trying to be controversial so they can publish an article. Just a theory and an old paper, from 2004. There is tons of recent literature about the cancer glycolysis pathways and they do stand scrutiny. I am talking about this article: Cancer metabolism: facts, fantasy, and fiction.
          Haven’t looked at the other one.

          Cheers,
          Helga

    2. so many paths for the freaking cancer. I hope that even if these routes are there, without glucose and glutamine they are not sufficient to avoid apoptosis. Probably it depends on the cancer type too.

  3. Dear Daniel,

    Thanks for calling my attention to this article. You are incredibly smart, I am amazed. I indeed had two beers last night and my condition was not as good as a day before. I assume the alcohol quickly gets transformed into acetate, which then fuels the cancer cells. Is it easy to get the Garcinia supplement and if you know HCA is effective? The wikipedia article claims it has not proven effective against obesity but avoids the topic of cancer.

      1. I’m very impressed and i feel lucky.
        I understand that HCA targets multiple sides of the same problem
        I read some places that cancer cells also “breathe” to produce energy, that fermentation is not the fully story.
        Any opinion about this?

        Thank you very much!!!
        Alex

        1. I agree. Fermentation is not the full story. This is why we often discussed here energy production pathways other than those based on fermentation (e.g. the use of ketones, glutamine, acetate, fatty acids). However, fermentation is probably the most relevant as it is a characteristic of most aggressive cancers + it is active in 97% of cancers.

  4. Extracellular Acidic pH Activates the Sterol Regulatory Element-Binding Protein 2 to Promote Tumor Progression.
    (pH-regulated SREBP2 target genes (e.g., ACSS2) affect tumor growth and malignancy)
    http://www.cell.com/cell-reports/abstract/S2211-1247(17)30171-7

    Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress.
    (ACSS2 expression would be controlled by SREBP-2)
    http://www.cell.com/cancer-cell/abstract/S1535-6108(14)00511-X

    A key regulator of cholesterol homoeostasis, SREBP-2, can be targeted in prostate cancer cells with natural products.
    ( Tocotrienols targeting the SREBP-2 pathway)
    http://www.biochemj.org/content/446/2/191.long/

    Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905210/

    1. Great references Frank! Very very helpful.
      I specifically like the connection ACSS2 – SREBP2 – Tocotrienols, and the reference regarding the dipyridamole added value in the statin based treatments. I will include them in the relevant treatment strategies, specifically the anti-colesterol one.
      Please keep sharing with us your valuable findings.

    2. Hey Frank,

      I specifically so much like this comment as it fits exactly the core of this website, i.e. findings tricks to improve the manipulate cellular processes in order to improve the effectiveness of various treatment strategies. I did not know about the feedback mechanism that reduces the effectiveness of statins and also did not know that ACSS2 can be controlled via SREB2 which is drug-able. I was actually in search for ACSS2 modulators as they may very much improve the ALA+HCA treatment strategy.
      Both of your findings were implemented across the website, where relevant, such as here https://www.cancertreatmentsresearch.com/reduce-cholesterol-in-cancer-cells-to-fight-cancer/
      With this, I think we have a very strong “anti” cholesterol and “anti” acetyl-CoA strategy.
      Thanks a lot again!

      Kind regards,
      Daniel

      1. I think the METABLOC (HCA + ALA) plus Tocotrienols and Coffee (Caffeine) will be a good idea.

        Rosuvastatin Increases Extracellular Adenosine Formation in Humans In Vivo.
        http://atvb.ahajournals.org/content/29/6/963.long

        Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A2A receptor.
        http://www.sciencedirect.com/science/article/pii/S0006295215005377
        https://www.researchgate.net/profile/Amos_Douvdevani/publication/281195178_Caffeine_promotes_anti-tumor_immune_response_during_tumor_initiation_Involvement_of_the_adenosine_A2A_receptor/links/560ce0d208ae6c9b0c42db82.pdf?origin=publication_detail

    1. Thanks Malypaet! The next question would be if we find references to support that 10mg/day orally will lead to the right plasma level to obtain the desired anti cancer effects. Or maybe we need to use more daily?

  5. My Story and a Question:
    Two years ago my prostate cancer was getting out of control after 20 years of fighting it. I started Metabloc in July 2015 and a miracle happened:
    My PSA stopped raising, fell by 50% and remained stable. Now it starts raising again. I am still under Metabloc.
    I recognise so much knowledge here. Would there be any recommendation what I should add to Metabloc for another try? I would v much appreciate any comment.
    Klaus (Bonn, Germany)

    1. Dear Klaus, can you please let me know first what you mean by Metabloc? Are you referring to the treatment done in Bahamas? Also, can you please let me know what was the dose you use, how was administered (oral or IV), and how often? What are the other supplements, drugs you used and you are using?
      The point is that first I would need to understand what you used and how to be able to give some ideas.
      Also, would help if you post your response on the prostate cancer page, here https://www.cancertreatmentsresearch.com/prostate-cancer/
      In this way others looking at prostate cancer can also follow the discussion.

      Thank you.

      Kind regards,
      Daniel

  6. D, this fits in very well with the MCT-1 3-BP angle. Recently I noticed that there are large trials ongoing now for a CT acetate scan for cancer. What is particularly interesting is that acetate as you noted enters cancer through MCT-1. SO, a CT acetate scan would give you a pinpoint accurate scan to tell you which 3-BP would enter. This could dramatically accelerate 3-BP clinical development. If you just give any old cancer patient 3-BP the results might not be so great. However, if you could select prospectively those patients that would have extreme responses, then there would hardly be much point in even bothering with the clinical trials. In the article that I saw, I found it surprising how many prostate cancer patients had positive CT acetate scans.

Leave a Reply